Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B003 and BL-B01D1+SI-B003 in urothelial carcinoma and solid tumors
NCT05965856Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SI-B003 in urothelial carcinoma (UC), prostate cancer (PCa), renal cell carcinoma (RCC), penile cancer, sponsored by Biokin Pharmaceutical. Started Dec 2023; status: recruiting.
02
Drugs
SI-B003
03
Conditions
urothelial carcinoma (UC)prostate cancer (PCa)renal cell carcinoma (RCC)penile cancer
Beyond the preview
Go deeper on NCT05965856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965856.